Nacia Faure — Endo Lab

2009

Behandlung mit einem intranasalen oder subkutan verabreichten LH-RH-Agonisten zur Unterdrückung der Ovarialfunktion bei der Behandlung der Endometriose

·doi:10.1159/000270926

rct 1988

Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis

American journal of obstetrics and gynecology ·doi:10.1016/0002-9378(88)90128-7

We have previously reported reversible hypogonadism induced by the intranasal administration of the luteinizing hormone-releasing hormone agonist buserelin as a new therapeutic approach for endometriosis. Thirteen patients were randomized t…

other 1987

LH-RH agonist treatment of endometriosis

Contributions to gynecology and obstetrics

1987

LH-RH Agonist Treatment of Endometriosis

·doi:10.1159/000414894

review 1986

Efficacy of different modalities of LHRH agonist (buserelin) administration on the inhibition of the pituitary-ovarian axis for the treatment of endometriosis

Progress in clinical and biological research

1985

Reversible down-regulation of pituitary-ovarian function induced by repetitive LH-RH agonist administration as a new approach for treatment and study of endometriosis in the human

·doi:10.1515/9783110861488-028

Reversible down-regulation of pituitary-ovarian function induced by repetitive LH-RH agonist administration as a new approach for treatment and study of endometriosis in the human was published in LH-RH and its Analogues on page 337.

1984

Efficacy and safety of LHRH agcnist treatment in 10 patients with endometriosis

·doi:10.1016/0022-4731(84)90443-6

1983

468 Pseudo-menopause induced by repetitive intranasal insufflation of a LHRH agonist (buserelin): A new approach for treatment of endometriosis

·doi:10.1016/0022-4731(83)91969-6